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Abstract
Here we report the design, synthesis, and biochemical characterization of a new chemical tool,
UNC0965. UNC0965 is a biotinylated version of our previously reported G9a chemical probe,
UNC0638. Importantly, UNC0965 maintains high in vitro potency and is cell penetrant. The
biotinylated tag of UNC0965 enables chemiprecipitation of G9a from whole cell lysates. Further,
the cell penetrance of UNC0965 allowed us to explore the localization of G9a on chromatin both
in vitro and in vivo.
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G9a is a lysine methyltransferase (KMT) responsible for catalyzing the mono- and
dimethylation of histone H3 lysine 9 (H3K9).[1–6] Its activity is linked to multiple biological
pathways and human diseases including cancer (reviewed in[7]). G9a is overexpressed in a
number of tumors;[8] specifically, it is associated with increased metastasis and invasion of
tumor cells in lung cancer.[9] Surprisingly, loss of G9a-dependent H3K9me2 (dimethylated
H3K9) has also been observed in various cancer cell lines.[10] This discrepancy underscores
the importance of further research into the biological role of G9a.
Chemical probes that demonstrate sufficient cellular potency and target selectivity can
greatly accelerate understanding of protein function.[11, 12] Here, we report the design,
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synthesis, and biochemical characterization of such a chemical tool, UNC0965. UNC0965 is
a biotinylated version of our previously reported G9a chemical probe UNC0638.[13]
UNC0965 displays low nanomolar in vitro potency, is active in cellular assays, and
selectively chemiprecipitates G9a from whole cell lysates. In addition, UNC0965 is a useful
tool for exploring the localization of G9a on chromatin both in vitro, and in vivo.
We previously reported the X-ray cocrystal structure of the G9a-UNC0638-SAH (S-
adenosyl-L-homocysteine) complex.[13] In this structure, UNC0638 adopted a conformation
that buried the 7-(3-pyrrolidin-1-yl-)propoxy side chain in the lysine binding channel, and
the isopropyl group of the 4-(N-isopropylpiperidin-4-ylamino) moiety was solvent exposed.
We reiterated our previous efforts with EZH2[14] by appending a biotin tag to the solvent
exposed region of UNC0638, which yielded UNC0965, a functionalized chemical tool for
biological applications (Figure 1a). We hypothesized that a relatively long linker (~20 atoms
from the piperidinyl nitrogen to the biotin carbonyl) would ensure that the biotin was at a
sufficient distance from the surface of G9a to permit access to streptavidin-conjugated
magnetic beads. This hypothesis was supported by docking studies using the G9a X-ray
structure (Figure 1b). As expected, UNC0965 docked in a nearly identical orientation to
UNC0638; with the 7-(3-pyrrolidin-1-yl)propoxy side chain embedded in the lysine binding
channel, and the biotin solvent exposed, well away from the surface of the protein.
The synthesis of UNC0965 is outlined in Scheme 1. Compound 6 was prepared from the
commercially available starting material (compound 1) according to the synthetic route
developed previously.[13, 15–17] Compound 8 was synthesized from commercially available
tert-butyl piperidin-4-ylcarbamate (7) in two straightforward steps. Nucleophilic aromatic
substitution of compound 6 with compound 8 gave compound 9, which is a UNC0638
derivative containing a terminal alkyne. We used this terminal alkyne to perform a copper
catalyzed click reaction with commercially available biotin-PEG3-azide to give compound
10, UNC0965.
We next confirmed that UNC0965 binds G9a and inhibits its catalytic activity. We used a
scintillation proximity assay as previously reported[18] to determine the IC50 of UNC0965
(Figure 2a). This assay is a direct measurement of the G9a catalyzed transfer of a tritiated
methyl group from 3H-SAM (S-adenosyl-L-methionine) to the histone peptide substrate.
UNC0965 showed potent inhibition, with an IC50 value of < 2.5 nM. This strong inhibition
of the G9a catalytic activity implied that UNC0965 would bind the protein tightly enough to
efficiently chemiprecipitate G9a from cell lysates.
UNC0965 was coupled to streptavidin-conjugated magnetic beads to chemiprecipitate G9a
from HEK 293T whole cell extracts (Figure 2b). Beads pre-incubated in the presence of
DMSO (1%) did not pull down G9a (Figure 2b, lane 2). UNC0965-coated streptavidin-
conjugated beads effectively pulled down G9a, while pre-incubation of the lysate with
UNC0638 blocked this interaction (Figure 2b, lanes 3 and 4). Additionally, UNC1152, a
negative control of UNC0638 that does not significantly inhibit G9a catalytic activity
(compound 26a in[18]), was unable to block the ability of UNC0965-coated beads to
chemiprecipitate G9a (Figure 2b, lanes 3 and 5). Therefore, UNC0965 chemiprecipitates
G9a from cell lysates, which further confirms that the biotin moiety of UNC0965 does not
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interfere with its binding to G9a. Future applications for this chemiprecipitation technique
could include proteomic analysis of precipitated proteins to identify G9a-binding partners.
To further characterize this chemical tool, we investigated whether UNC0965 could capture
G9a from formaldehyde crosslinked chromatin. Chromatin is a highly dynamic structure,
and an effective barrier to gene transcription. As such, it is frequently remodeled to create or
prevent access of transcription factors to underlying DNA sequences. Traditional antibody-
based chromatin immunoprecipitation (ChIP) was developed as a tool to provide a snapshot
of protein-DNA interactions in the dynamic chromatin environment (reviewed in[19–21]). In
a standard ChIP assay, a crosslinking reagent such as formaldehyde is used to covalently
attach proteins to DNA, the cells are lysed, and the chromatin is fragmented by sonication or
enzymatic digestion. An antibody is then used to immunoprecipitate a protein of interest
from the chromatin extract and the associated DNA sequences are analyzed by methods such
as quantitative PCR (qPCR) or next-generation sequencing (ChIP-seq). We hypothesized
that UNC0965 could substitute for an antibody to precipitate G9a protein in a method
referred to as chemical inhibitor chromatin precipitation (chem-ChIP).[22]
Use of a functionalized chemical tool for chromatin precipitation has distinct advantages
over an antibody. First, such chemical tools can be easily synthesized at low cost, and
eliminate the batch-to-batch variability common with antibody reagents. Second, the biotin
tag can be designed to be solvent exposed for chemical tools that have a well-defined mode
of binding. This design has a potential added advantage over traditional ChIP, where
crosslinking can prevent access of an antibody to the protein of interest. Third, chemical
tools can be cell permeable, which allows cell treatment prior to crosslinking. This in vivo
chem-ChIP method would be particularly well suited for proteins that are difficult to
precipitate after crosslinking due to antibody epitope masking. Therefore, we tested the
ability of UNC0965 to precipitate G9a from chromatin extracted from crosslinked cells (in
vitro chem-ChIP), and chromatin generated from cells treated with the compound prior to
crosslinking (in vivo chem-ChIP) and compared these results to the normal antibody
method.
Using traditional antibody ChIP, we identified four chromosomal regions in HEK 293T cells
(Supplemental Table S1) that showed a significant fold change in G9a occupancy over
background when compared to a negative control region near the GAPDH gene (Figure 3a).
We performed in vitro chem-ChIP using the same protocol used for antibody ChIP. In place
of the G9a antibody and IgG control, we used streptavidin-conjugated magnetic beads pre-
incubated with UNC0965 and DMSO, respectively. We then examined the identified G9a
occupied chromosomal regions by qPCR (Figure 3b). The UNC0965 in vitro chem-ChIP
showed a greater than 5-fold increase over DMSO at each chromosomal region. The
difference between the G9a antibody ChIP signal and the IgG signal was less significant (p
< 0.5 to p < 0.01) (Figure 3a), than the signal for UNC0965 in vitro chem-ChIP compared to
DMSO (p < 0.01 to p < 0.001). Thus, UNC0965 effectively captures G9a in an in vitro ChIP
assay, and in this case with a better G9a signal over background than the antibody ChIP.
As noted earlier, unlike antibodies, cell permeable small-molecule tools can be used to pre-
bind the target in cells prior to crosslinking. We assessed cellular activity of UNC0965 using
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an in-cell western assay reported previously.[13] Treatment of cells for 48 hours with
increasing concentrations of UNC0965 resulted in a decrease in H3K9me2 (IC50 = 3.3 ± 1.2
µM), with low cell toxicity (EC50 > 50 µM) (Figure 4a). While UNC0965 has lower cell
permeability compared to UNC0638,[13] it shows sufficient inhibition of H3K9me2 to be
useful for cell-based assays.
For the in vivo chem-ChIP assay, we wanted to pulse the cells with the compound, rather
than treat for several days, in order to minimize any effects of G9a inhibition on its
chromatin localization. Therefore, we grew HEK 293T cells to 80% confluency, and then
exposed the cells to 5 µM UNC0965 or 0.05% (volume equivalent) DMSO for 15 minutes
prior to formaldehyde crosslinking. We then performed the standard antibody ChIP protocol
(see Supplemental Methods) except the precipitation step was performed using streptavidin-
conjugated magnetic beads. Cells treated with UNC0965 showed a significant average
change in G9a occupancy over DMSO-treated cells (p < 0.01) (Figure 4b), which was very
comparable to the in vitro chem-ChIP results (Figure 3b). These data demonstrate that even
with compound pre-treatment of the cells, the biotin moiety on UNC0965 remains solvent
exposed after formaldehyde crosslinking, confirming that UNC0965 is a useful chemical
tool for in vivo chem-ChIP studies and could be used in additional cellular applications.
Our success with UNC0965 and G9a highlights methods to convert highly selective
chemical probes into extremely valuable tools that may aide in understanding biological
questions. The in vivo chem-ChIP technique could be an alternative method for targets that
have no suitable ChIP-grade antibody due to masking of the appropriate epitope after
crosslinking. In fact, use of a labeled chemical tool could prevent the need for
overexpression of a tagged protein. We noted that the signal to noise ratio was lower for the
antibody ChIP compared to both the in vitro and in vivo chem-ChIP assays. Thus, it would
be interesting to compare genome-wide occupancy of G9a between all three methods to




Chromatin was prepared from HEK 293T cells as described for the antibody ChIP. Each
ChIP contained chromatin from approximately 8x106 cells. Streptavidin-conjugated
magnetic beads (Dynabeads® M-280 streptavidin, Life Technologies #11205D, 250 µg per
chemiprecipitation) were washed 3 times with 500 µL TBST (20 mM Tris-HCl, pH 8.0, 150
mM NaCl, 0.1% Tween-20), diluted in 100 µL TBST, and 4 µL of 10 mM UNC0965 was
added, followed by rotation on an end-over-end rotator for 1 hour at room temperature to
saturate the beads. After binding, the beads were washed with TBST (500 µL×3) to remove
excess unbound compound. Chromatin was then added to the beads and the mixture was
placed on a rotator at 4°C overnight. The next morning, tubes were removed from the
rotator, and supernatant was aspirated from the beads. The beads were washed (500 µL×3)
with ChIP wash buffer (0.1% SDS, 1% TritonX-100, 2 mM EDTA, 150 mM NaCl, 20 mM
Tris, pH=8.0) followed by one wash with 500 µL of ChIP final wash buffer (1% SDS, 1%
TritonX-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl, pH 8.0). During each wash,
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the sample was rotated at room temperature for 3 minutes. The washed beads were
resuspended in 200 µL TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0) with 20 µg
proteinase K, and the contents were transferred into a PCR tube. The mixture was incubated
at 55°C, for 30 minutes followed by 2 hours at 80°C to reverse the crosslinks. The DNA in
the collected supernatant was then purified as described in Active Motif ChIP-IT® High
Sensitivity kit #53040.
In vivo chem-ChIP
HEK 293T cells were grown to 80% confluency on 15 cm plates as described. Cells were
treated with 5 µM UNC0965 for 15 minutes prior to formaldehyde crosslinking. Chromatin
was prepared as described for the antibody ChIP. Each chem-ChIP represented
approximately 8x106 cells. Streptavidin-conjugated magnetic beads (Dynabeads® M-280
streptavidin, Life Technologies #11205D, 500 µg per chemiprecipitation) were washed 3
times with 500 µL TBST (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween-20).
Chromatin was then added to the beads and the mixture was placed on a rotator at 4°C
overnight. Wash and DNA purification steps were performed as described in the method for
in vitro chem-ChIP, above.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Design of UNC0965. a) G9a-UNC0638-SAH co-crystal structure (PDB: 3RJW) was previously solved and demonstrated that
the N-isopropyl group of UNC0638 is solvent exposed. We took advantage of this chemical handle and designed a biotinylated
derivative, UNC0965. b) Docking of UNC0965 into the G9a crystal structure predicts a similar binding mode as UNC0638.
Importantly, the biotin moiety of UNC0965 is solvent exposed and suitable for streptavidin capture.
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In vitro characterization of UNC0965. a) UNC0965 shows potent inhibition (IC50 < 2.5 nM) of G9a catalytic activity in an in
vitro scintillation proximity assay. Experiments were performed in duplicate. b) Streptavidin-conjugated magnetic beads pre-
coated with UNC0965 selectively chemiprecipitate G9a from HEK 293T cell lysates. G9a western blot indicates that UNC0965-
treated beads (lane 3) chemiprecipitate G9a compared to DMSO-treated beads (lane 2). This interaction can be blocked or
retained, by pretreating lysate with UNC0638 (lane 4) or its negative control UNC1152 (lane 5), respectively. The large (G9aL)
and small (G9aS) isoforms of G9a are indicated. The asterisk (*) denotes a background band. These data are representative of
three biological replicates.
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G9a occupancy on chromatin can be determined using antibody ChIP or in vitro chem-ChIP with UNC0965. a) ChIP using G9a
antibody or IgG control followed by qPCR. b) In vitro chem-ChIP with UNC0965-coated streptavidin-conjugated magnetic
beads followed by qPCR. PCR primer sets correspond to chromosomal regions (CR) occupied by G9a as well as a GAPDH
control region that shows no G9a occupancy. Chromosomal regions assayed include: CR1 (white), CR2 (checkered), CR3
(grey), and CR4 (black), and GAPDH (light grey). Error bars represent the standard deviation of three biological replicates.
Statistical significance between DMSO and UNC0965 chem-ChIP for each region was determined by an unpaired t-test and
indicated by asterisks (* = p < .05, ** = p < .01, *** = p < .001).
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UNC0965 is cell penetrant and can be used for in vivo chem-ChIP assays. a) In-cell western assay of MDA-MB-231 cells
treated with UNC0965 and assayed for total cellular H3K9me2 levels. UNC0965 reduces cellular levels of H3K9me2 (light grey
squares; IC50 = 3.3 ± 1.2 µM) and is not toxic in the compound concentration range tested (grey circles; EC50 > 50 µM). Error
bars represent the standard deviation of 3 biological replicates. These data confirm that UNC0965 is cell penetrant. b) In vivo
chem-ChIP. HEK 293T cells were treated with UNC0965 (5 µM) or DMSO (0.05%) for 15 minutes, crosslinked with
formaldehyde, and then chromatin was isolated. ChIP was performed using streptavidin-conjugated magnetic beads followed by
qPCR. PCR primer sets correspond to chromosomal regions (CR) occupied by G9a as well as a GAPDH control region that
shows no G9a occupancy. Chromosomal regions assayed include: CR1 (white), CR2 (checkered), CR3 (grey), and CR4 (black),
and GAPDH (light grey). Error bars represent the standard deviation of three biological replicates. Statistical significance
between DMSO and UNC0965 chem-ChIP for each region was determined by an unpaired t-test and indicated by asterisks (** =
p < .01, *** = p < .001).
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Synthesis of UNC0965. Reagents and Conditions: (a) 1-Chloro-3-iodopropane, K2CO3, CH3CN, reflux; (b) HNO3, Ac2O, 0 °C
to RT, 75% over two steps; (c) pyrrolidine, K2CO3, NaI, cat. tetrabutylammonium iodide, CH3CN, reflux, 81%; (d) Fe dust,
NH4OAc, EtOAc-H2O, reflux, 63%; (e) 4 N HCl, dioxane, cyclohexanecarbonitrile; (f) N,N-diethylaniline, POCl3, reflux, 47%
over two steps; (g) hex-5-yn-1-yl 4-methylbenzenesulfonate, K2CO3, DMF, 60 °C, 88%; (h) TFA, DCM, rt, 99%; (i) 1-(hex-5-
yn-1-yl)piperidin-4-amine·2TFA (8), K2CO3, DMF, 60 °C, 81%; (j) biotin-PEG3-azide, cat. Cu(CH3CN)4PF6, DCM, rt, 92%.
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